← Back to patent-cliff list
Surzetoclax
Tier C — Watch / tradeSurzetoclax
AbbVie
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BCL2
Indications (approved)：Multiple myeloma, Chronic lymphocytic leukaemia
Regional status
US
Phase II
2025-07-23
EU
Phase II
2025-07-23
China
-
Japan
Phase II
2025-07-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Surzetoclax?
Approved indications include: Multiple myeloma, Chronic lymphocytic leukaemia.
When does the Surzetoclax patent expire?
No public expiry year is available for Surzetoclax yet; this page updates once verified.
How do I get a quote for Surzetoclax intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30